A Noninvasive Prenatal Testing Success Story: Rachel and Lee

3 June 2016

After experiencing a miscarriage, couple Rachel and Lee worried whether they could conceive a healthy child. They decided to try noninvasive prenatal testing (NIPT) - a screening test from Illumina. The test screens for multiple fetal chromosomal aneuploidies using a single maternal blood draw. Now, with a healthy daughter, the couple reflects on the value of NIPT and the peace of mind it gave them throughout their pregnancy. Learn more about the latest advances in reproductive and genetic health solutions from Illumina. [link to RGH page http://www.illumina.com/clinical/reproductive-genetic-health.ilmn]

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.